300966 共同药业
已收盘 08-01 15:00:00
资讯
新帖
简况
湖北板块盘中拉升，共同药业涨13.08%
市场透视 · 08-01 01:37
湖北板块盘中拉升，共同药业涨13.08%
异动快报：共同药业（300966）7月31日9点37分触及涨停板
证券之星 · 07-31
异动快报：共同药业（300966）7月31日9点37分触及涨停板
熊去氧胆酸概念盘中拉升，共同药业涨0.57%
市场透视 · 07-21
熊去氧胆酸概念盘中拉升，共同药业涨0.57%
共同药业2024亏损 2021上市中信证券保荐两募资共6亿
海峡网 · 06-30
共同药业2024亏损 2021上市中信证券保荐两募资共6亿
共同药业：公司始终高度重视市值管理工作
证券之星 · 06-20
共同药业：公司始终高度重视市值管理工作
共同药业(300966.SZ)发布一季度业绩，归母净利润108.21万元，下降69.50%
智通财经 · 04-28
共同药业(300966.SZ)发布一季度业绩，归母净利润108.21万元，下降69.50%
图解共同药业一季报：第一季度单季净利润同比减69.50%
证券之星 · 04-28
图解共同药业一季报：第一季度单季净利润同比减69.50%
共同药业(300966)3月31日股东户数1.29万户，较上期增加0.4%
证券之星 · 04-28
共同药业(300966)3月31日股东户数1.29万户，较上期增加0.4%
太平洋：给予共同药业增持评级
证券之星 · 04-27
太平洋：给予共同药业增持评级
共同药业：创新药研发属于公司的商业秘密
证券之星 · 04-25
共同药业：创新药研发属于公司的商业秘密
【共同药业：2024年净亏损2759.11万元，由盈转亏】共同药业公告，2024年营业收入5.37亿元，同比下降5.26%。归属于上市公司股东的净亏损2759.11万元，去年同期净利润2300.5万元，由盈转亏。基本每股收益-0.24元/股。公司计划不派发现金红利，不送红股，不以公积金转增股本。
金融界 · 04-23
【共同药业：2024年净亏损2759.11万元，由盈转亏】共同药业公告，2024年营业收入5.37亿元，同比下降5.26%。归属于上市公司股东的净亏损2759.11万元，去年同期净利润2300.5万元，由盈转亏。基本每股收益-0.24元/股。公司计划不派发现金红利，不送红股，不以公积金转增股本。
共同药业：回购期限自董事会审议之日起12个月内
证券之星 · 04-17
共同药业：回购期限自董事会审议之日起12个月内
共同药业(300966.SZ)拟斥2000万元至3000万元实施回购
智通财经 · 02-21
共同药业(300966.SZ)拟斥2000万元至3000万元实施回购
共同药业最新公告：拟以2000万元至3000万元回购股份
证券之星 · 02-21
共同药业最新公告：拟以2000万元至3000万元回购股份
【企业动态】共同药业新增1件法院诉讼，案由为与公司有关的纠纷案件执行
证券之星 · 02-07
【企业动态】共同药业新增1件法院诉讼，案由为与公司有关的纠纷案件执行
2月5日共同药业发布公告，股东减持39.47万股
证券之星 · 02-05
2月5日共同药业发布公告，股东减持39.47万股
共同药业(300966.SZ)遭股东丹创投减持39.47万股
智通财经 · 02-05
共同药业(300966.SZ)遭股东丹创投减持39.47万股
太平洋：给予共同药业增持评级，目标价位19.0元
证券之星 · 01-19
太平洋：给予共同药业增持评级，目标价位19.0元
加载更多
公司概况
公司名称：
湖北共同药业股份有限公司
所属行业：
医药制造业
上市日期：
2021-04-09
主营业务：
湖北共同药业股份有限公司的主营业务是甾体药物原料的研发、生产及销售。公司的主要产品是4-雄烯二酮（4-AD）、雄二烯二酮（ADD）、双降醇（BA）、9-羟基雄烯二酮（9-OH-AD）。
发行价格：
8.24
{"stockData":{"symbol":"300966","market":"SZ","secType":"STK","nameCN":"共同药业","latestPrice":26.68,"timestamp":1754031807000,"preClose":24.61,"halted":0,"volume":29784444,"delay":0,"changeRate":0.0841,"floatShares":76665000,"shares":114999999,"eps":-0.2608,"marketStatus":"已收盘","change":2.07,"latestTime":"08-01 15:00:00","open":26.26,"high":28.63,"low":25.68,"amount":808000000,"amplitude":0.1199,"askPrice":26.68,"askSize":467,"bidPrice":26.67,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-0.2608,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754271000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.61,"symbolType":"stock","openAndCloseTimeList":[[1754011800000,1754019000000],[1754024400000,1754031600000]],"highLimit":27.07,"lowLimit":22.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":115279416,"isCdr":false,"pbRate":3.44,"roa":"--","roe":"0.12%","epsLYR":-0.24,"committee":-0.857645,"marketValue":3076000000,"turnoverRate":0.3885,"status":0,"floatMarketCap":2045000000},"requestUrl":"/m/hq/s/300966","defaultTab":"news","newsList":[{"id":"2556850546","title":"湖北板块盘中拉升，共同药业涨13.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556850546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556850546?lang=zh_cn&edition=full","pubTime":"2025-08-01 09:37","pubTimestamp":1754012245,"startTime":"0","endTime":"0","summary":"08月01日，湖北板块盘中拉升，截至09点37分，湖北板块整体指数上涨0.54%，报2673.220点。从个股上来看，该板块的成分股中，共同药业涨13.08%，汉商集团、回盛生物2只股涨幅超过5%。从资金上来看，截止发稿，湖北板块主力净流入为-4.86亿，其中居然智家受到资金热捧，主力净流入3227.10万；拉长时间线来看，该板块近20日主力资金净流入-158.85亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080109372594c797f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080109372594c797f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0209","BK0239","300966","600774"],"gpt_icon":0},{"id":"2555609079","title":"异动快报：共同药业（300966）7月31日9点37分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2555609079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555609079?lang=zh_cn&edition=full","pubTime":"2025-07-31 09:40","pubTimestamp":1753926044,"startTime":"0","endTime":"0","summary":"证券之星7月31日盘中消息，9点37分共同药业触及涨停板。目前价格24.61，上涨19.99%。其所属行业化学制药目前上涨。领涨股为南新制药。该股为辅助生殖，化学原料药，新冠病毒防治概念热股，当日辅助生殖概念上涨2.97%，化学原料药概念上涨0.16%，新冠病毒防治概念上涨0.02%。7月30日的资金流向数据方面，主力资金净流入57.77万元，占总成交额0.29%，游资资金净流入393.49万元，占总成交额1.99%，散户资金净流出451.25万元，占总成交额2.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100008404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2553447238","title":"熊去氧胆酸概念盘中拉升，共同药业涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553447238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553447238?lang=zh_cn&edition=full","pubTime":"2025-07-21 09:56","pubTimestamp":1753062985,"startTime":"0","endTime":"0","summary":"07月21日，熊去氧胆酸概念盘中拉升，截至09点56分，熊去氧胆酸概念整体指数上涨0.50%，报1340.160点。从个股上来看，该概念的成分股中，共同药业涨0.57%，海辰药业、阿拉丁、九典制药涨幅居前。从资金上来看，截止发稿，熊去氧胆酸概念主力净流入为-1.10亿，其中广生堂受到资金热捧，主力净流入1112.53万；拉长时间线来看，该板块近20日主力资金净流入-15.25亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721095625954a3961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721095625954a3961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300966","BK0216","BK0239","688179"],"gpt_icon":0},{"id":"2547816061","title":"共同药业2024亏损 2021上市中信证券保荐两募资共6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2547816061","media":"海峡网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547816061?lang=zh_cn&edition=full","pubTime":"2025-06-30 16:35","pubTimestamp":1751272500,"startTime":"0","endTime":"0","summary":"共同药业本次发行募集资金总额23,896.00万元；扣除发行费用后，募集资金净额为19,418.21万元。2022年12月13日，共同药业发布创业板向不特定对象发行可转换公司债券上市公告书。共同药业表示，本次发行可转换公司债券募集资金扣除承销及保荐费用后的余额已由保荐机构于2022年12月2日汇入公司指定的募集资金账户。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-30/doc-infcvyah9812058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997244956.HKD","300966","LU0405327148.USD","BK0028","LU1064131003.USD","LU0405327494.USD","BK0239","LU1655091616.SGD","BK0196","BK1516","BK0276","BK0188","LU1997245177.USD","LU2495084118.USD","LU1328615791.USD","LU1720050803.USD","LU2148510915.USD","BK0012","LU1064130708.USD","BK1564","BK1147","BK0183","LU2289578879.USD","BK1521","06030","LU1997245094.SGD","LU1794554557.SGD","600030"],"gpt_icon":0},{"id":"2544143844","title":"共同药业：公司始终高度重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2544143844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544143844?lang=zh_cn&edition=full","pubTime":"2025-06-20 15:07","pubTimestamp":1750403236,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业(300966)06月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司如何提升经验业绩，如何做好市值管理?共同药业回复：尊敬的投资者，您好，公司始终高度重视市值管理工作，将会继续聚焦主业，努力做好生产经营，推动公司内在价值和市值的提升，以回报广大投资者。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000016404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2530015834","title":"共同药业(300966.SZ)发布一季度业绩，归母净利润108.21万元，下降69.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530015834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530015834?lang=zh_cn&edition=full","pubTime":"2025-04-28 20:21","pubTimestamp":1745842904,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)发布2025年第一季度报告，该公司营业收入为1.39亿元，同比增长13.90%。归属于上市公司股东的净利润为108.21万元，同比减少69.50%。归属于上市公司股东的扣除非经常性损益的净利润为133.66万元，同比减少61.42%。基本每股收益为0.01元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300966"],"gpt_icon":0},{"id":"2530748684","title":"图解共同药业一季报：第一季度单季净利润同比减69.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530748684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530748684?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:04","pubTimestamp":1745838295,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业2025年一季报显示，公司主营收入1.39亿元，同比上升13.9%；归母净利润108.21万元，同比下降69.5%；扣非净利润133.66万元，同比下降61.42%；负债率65.26%，投资收益-27.02万元，财务费用1037.1万元，毛利率24.24%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800029356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2530424566","title":"共同药业(300966)3月31日股东户数1.29万户，较上期增加0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530424566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530424566?lang=zh_cn&edition=full","pubTime":"2025-04-28 17:22","pubTimestamp":1745832125,"startTime":"0","endTime":"0","summary":"证券之星消息，近日共同药业披露，截至2025年3月31日公司股东户数为1.29万户，较12月31日增加51.0户，增幅为0.4%。在化学制药行业个股中，共同药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.17万户。从股价来看，2024年12月31日至2025年3月31日，共同药业区间涨幅为0.06%，在此期间股东户数增加51.0户，增幅为0.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042800026853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2530101865","title":"太平洋：给予共同药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2530101865","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530101865?lang=zh_cn&edition=full","pubTime":"2025-04-27 10:05","pubTimestamp":1745719517,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对共同药业进行研究并发布了研究报告《2024年业绩符合市场预期，产能大规模投放》，给予共同药业增持评级。 投资建议 公司产能陆续投放，盈利能力有望随产能利用率的提升而修复，预测公司2025/26/27年营收为6.17/7.41/8.89亿元，归母净利润为-0.31/-0.15/0.53亿元，对应26/27年PE为121/34X，持续给予“增持”评级。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700003963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300966"],"gpt_icon":0},{"id":"2530608972","title":"共同药业：创新药研发属于公司的商业秘密","url":"https://stock-news.laohu8.com/highlight/detail?id=2530608972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530608972?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:30","pubTimestamp":1745569837,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业(300966)04月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司创新药研发进度如何共同药业回复：尊敬的投资者，您好，公司主营业务是甾体药物起始物料、中间体的研发、生产和销售，创新药研发属于公司的商业秘密，具体请以公司公告披露的信息为准，感谢的关注，谢谢！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500025266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","300966","BK1161","159992","BK0239"],"gpt_icon":0},{"id":"2529686411","title":"【共同药业：2024年净亏损2759.11万元，由盈转亏】共同药业公告，2024年营业收入5.37亿元，同比下降5.26%。归属于上市公司股东的净亏损2759.11万元，去年同期净利润2300.5万元，由盈转亏。基本每股收益-0.24元/股。公司计划不派发现金红利，不送红股，不以公积金转增股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529686411","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529686411?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:21","pubTimestamp":1745414482,"startTime":"0","endTime":"0","summary":"共同药业公告，2024年营业收入5.37亿元，同比下降5.26%。归属于上市公司股东的净亏损2759.11万元，去年同期净利润2300.5万元，由盈转亏。基本每股收益-0.24元/股。公司计划不派发现金红利，不送红股，不以公积金转增股本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/23212149805484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300966"],"gpt_icon":0},{"id":"2528125967","title":"共同药业：回购期限自董事会审议之日起12个月内","url":"https://stock-news.laohu8.com/highlight/detail?id=2528125967","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528125967?lang=zh_cn&edition=full","pubTime":"2025-04-17 20:51","pubTimestamp":1744894282,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业(300966)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的回购是否持续进行，目前股价这么低，很好的回购机会，请把握好！共同药业回复：尊敬的投资者，您好，感谢您的建议，回购期限自董事会审议之日起12个月内，公司会根据市场情况适时推进回购工作，每月初会披露截至上月末的回购进展情况，感谢您的关注，谢谢!以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041700034439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2513265468","title":"共同药业(300966.SZ)拟斥2000万元至3000万元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2513265468","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513265468?lang=zh_cn&edition=full","pubTime":"2025-02-21 19:11","pubTimestamp":1740136301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)公告，公司拟使用自有资金及浦发银行提供的股票回购专项贷款资金实施回购公司股份方案。回购资金总额不低于人民币2000万元(含)，不超过人民币3000万元(含);价格不超过人民币23.84元/股。回购期限自董事会审议通过回购股份方案之日起12个月内。目前公司已取得浦发银行出具的《贷款承诺函》，承诺为公司回购A股股份提供专项贷款支持，借款金额最高不超过人民币2700万元(含)，借款期限为3年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2513268780","title":"共同药业最新公告：拟以2000万元至3000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2513268780","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513268780?lang=zh_cn&edition=full","pubTime":"2025-02-21 18:30","pubTimestamp":1740133831,"startTime":"0","endTime":"0","summary":"共同药业公告称，公司计划使用自有资金及金融机构提供的股票回购专项贷款资金，以集中竞价方式回购公司股份，回购价格不超过23.84元/股，资金总额不低于2,000万元（含），不超过3,000万元（含）。回购的股份将用于股权激励或员工持股计划，若未能在回购完成后三年内使用完毕，将依法注销。公司已取得浦发银行出具的《贷款承诺函》，承诺为公司回购A股股份提供最高不超过2,700万元（含）的专项贷款支持。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100034783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2509772654","title":"【企业动态】共同药业新增1件法院诉讼，案由为与公司有关的纠纷案件执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2509772654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509772654?lang=zh_cn&edition=full","pubTime":"2025-02-08 05:58","pubTimestamp":1738965493,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，2月7日共同药业（300966）新增1件法院诉讼如下：案号：（2025）鄂0111执1026号法院：武汉市洪山区人民法院案由：与公司有关的纠纷案件执行申请人：苏某某被执行人：湖北共同药业股份有限公司案件类型：执行立案日期：2025年2月7日数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020800054060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2509095104","title":"2月5日共同药业发布公告，股东减持39.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509095104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509095104?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:01","pubTimestamp":1738753278,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日共同药业发布公告《共同药业:关于控股股东、实际控制人的一致行动人减持计划期限届满暨减持结果的公告》，其股东丹江口市共同创新投资合伙企业(有限合伙)于2024年10月28日至2025年1月27日间合计减持39.47万股，占公司目前总股本的0.3424%，变动期间该股股价下跌21.51%，截止1月27日收盘报15.4元。股东增减持详情见下表：根据共同药业2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020500029199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2509140598","title":"共同药业(300966.SZ)遭股东丹创投减持39.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509140598","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509140598?lang=zh_cn&edition=full","pubTime":"2025-02-05 18:32","pubTimestamp":1738751560,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)公告，公司收到丹创投、张欣出具的《关于股份减持计划期限届满的告知函》，丹创投减持39.47万股，张欣未减持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2504463499","title":"太平洋：给予共同药业增持评级，目标价位19.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504463499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504463499?lang=zh_cn&edition=full","pubTime":"2025-01-19 19:05","pubTimestamp":1737284717,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对共同药业进行研究并发布了研究报告《Q4业绩符合市场预期，利润端短暂承压》，本报告对共同药业给出增持评级，认为其目标价位为19.00元，当前股价为15.45元，预期上涨幅度为22.98%。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011900001727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","601099"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1754264401827,"stockEarnings":[{"period":"1week","weight":0.3571},{"period":"1month","weight":0.4375},{"period":"3month","weight":0.6613},{"period":"6month","weight":0.7325},{"period":"1year","weight":0.6388},{"period":"ytd","weight":0.6541}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0857},{"period":"6month","weight":0.0952},{"period":"1year","weight":0.214},{"period":"ytd","weight":0.0621}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北共同药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12915人(较上一季度增加0.40%)","perCapita":"5936股","listingDate":"2021-04-09","address":"湖北省襄阳市宜城市小河镇高坑一组","registeredCapital":"11527万元","survey":" 湖北共同药业股份有限公司的主营业务是甾体药物原料的研发、生产及销售。公司的主要产品是4-雄烯二酮（4-AD）、雄二烯二酮（ADD）、双降醇（BA）、9-羟基雄烯二酮（9-OH-AD）。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"共同药业,300966,共同药业股票,共同药业股票老虎,共同药业股票老虎国际,共同药业行情,共同药业股票行情,共同药业股价,共同药业股市,共同药业股票价格,共同药业股票交易,共同药业股票购买,共同药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}